Oura’s healthcare ambitions take shape

Today, healthcare isn’t what’s driving Oura’s business — technically. The revenue Oura receives from contracts with health plans and providers is “de minimis” right now,

Lilly reports 20% weight loss with amylin-targeting drug

Eli Lilly has raised the stakes in the obesity market with positive midstage data for its amylin-targeting drug eloralintide.

Subscribe for Updates

Copyright 2025 dijee Intelligence Ltd.   dijee Intelligence Ltd. is a private limited company registered in England and Wales at Media House, Sopers Road, Cuffley, Hertfordshire, EN6 4RY, UK registeration number 16808844